Abstract: A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance.

Abstract: This document relates to non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising cabazitaxel and human serum albumin. This document also relates to compositions consisting essentially of cabazitaxel and human serum albumin.

Abstract: Embodiments of the present disclosure provide for structures including an alloy of calcium, strontium, and magnesium.

Abstract: A group of inventions relates to pharmaceutics and refers to a method for preparing a liposomal composition and a pharmacologically active liposomal composition for ophthalmotherapy prepared by this method. The method is implemented by creating a mixture of solutions of latanoprost, egg phosphatidylcholine and cholesterol in organic solvents, vacuum drying thereof, emulsifying in an aqueous medium, and dispersing an emulsion under pressure. According to the invention, a solution of dipalmytoyl phosphatidylglycerol is introduced into the mixture of solutions, wherein latanoprost, egg phosphatidylcholine, and cholesterol are dissolved in ethyl alcohol, while dipalmytoyl phosphatidylglycerol is dissolved in a mixture of ethyl alcohol and chloroform. The emulsifying of the dried mixture is conducted by a lactose solution in a pH 7.1 buffer, while the dispersing of the emulsion is conducted at a stepwise pressure increase from 300 to 800 at followed by a sterilizing filtration and a freeze drying.

Abstract: The present invention provides a betaine compound for use in the prevention of obesity, excessive fat accumulation and/or metabolic disorders associated with either of the foregoing in a subject, wherein the prevention comprises administering the betaine compound directly to the subject during infancy or, alternatively, to the subject's mother during breast-feeding. Also provided are compositions comprising an effective amount of betaine compound together with one or more pharmaceutically or edible acceptable excipients and/or carriers for this use.

Abstract: A method includes combining nicotine with a liquid carrier to form a liquid mixture and spray drying the liquid mixture to form a first plurality of particles. The first pluralities of particles are then milled to form a second plurality of particles.

Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.

Abstract: Tetraniliprole containing formulations and methods for using them for controlling rootworm infestation are discussed. The formulations of the present invention provide improved delivery active ingredients by the ability to provide substantially higher degree of control as compared to other diamide counterparts.

Abstract: The invention provides a cosmetic having strong resistance to contact with water, clothing, fingers, and abrasion with little decline (post-contact) in the cosmetic effects such as UV blocking protection as well as excellent feel on use. The cosmetic contains: (A) plate-shaped powder, (B) 6-40% by mass UV absorber, and (C) cationic surfactant.

Abstract: A composition comprising collagen and honey can be produced by addition of an aqueous solution of honey to an aqueous suspension of collagen. The composition is for use in medicine and particularly for use in the treatment of a wound. A method for treatment of a wound comprises administering the composition topically to the skin of a patient.

Abstract: In accordance with, the present invention, there is provided an antimicrobial composition comprising an aqueous solution containing copper and/or zinc ions, optionally a hydroxide salt, and phosphorous acid. The composition, is additionally sporicidal and scleroticidal when combined with a salt of nitrous acid such as sodium nitrite. The present invention may also include chemicals containing the phosphite or phosphonaie group (PO/l which can inhibit the formation of scierotia at concentrations that are readily achievable for agricultural applications. Compositions of the present invention, inhibit, scierotia formation by fungi and may therefore be used in the field to prevent the continuation and advancement of pathogenie fungi.

Abstract: A photoprotective composition can be utilized for a variety of cosmetic compositions. A photoprotective composition comprises one or more photoactive agents, and a synergistic combination of polymers. The photoprotective composition can provide a substantially a complete film. The photoprotective composition may comprise an alkyl dimethicone, a polymer with ester linkages, and a phenyl silicone or stearate. The photoprotective composition can further comprise abietic acid and ester derivatives. The photoprotective composition can be a liquid such that it is easily and consistently dispensed from a bottle, pump or spray.

Abstract: Formulations comprising cycloserine compounds and one or more enteric materials in a solid dosage form, and uses thereof for treating and/or reducing the risk of a neuropsychiatric disorder or tuberculosis.

Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Abstract: The invention is directed to a topical composition comprising one or more topical active ingredients, one or more nonionic surfactants and one or more viscosity enhancers. The invention is further directed to a method of treating topical conditions comprising applying a composition of the present invention to a subject in need thereof.

Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. The dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one magnesium salt, and optionally potassium salt, and calcium salt. According to the invention the glucose and the at least one magnesium salt, are present as anhydrous components in the dialysis acid precursor composition.

Abstract: A method of preventing COVID-19 infection in an individual, the method comprising the steps of providing an individual that is not infected with COVID-19; administering four antimicrobials to the individual, wherein the antimicrobials comprise: hydroxychloroquine; vitamin C; vitamin D; and zinc; and monitoring the individuals condition over a pre-determined amount of time to determine the individual does not become infected with COVID-19. A method of treating an individual infected with COVID-19, the method comprising the steps of: providing an individual infected with COVID-19; administering five antimicrobials to the individual, wherein the antimicrobials comprise: hydroxychloroquine; azithromycin; vitamin C; vitamin D; and zinc; and monitoring the individuals condition over a pre-determined period of time to determine whether the individual is no longer infected with COVID-19.

Abstract: Described herein are methods and formulations for treating, inhibiting, or ameliorating cellulite. Aspects described herein relate to formulations including a saline solution, reactive oxygen species, a rheology agent, an emollient, and a pH modifier and methods of using these formulations for treating, ameliorating, or inhibiting cellulite.

Abstract: Disclosed herein is a method for treating a cancer, the method includes following operations. A pharmaceutical composition is administered to a subject in need. The pharmaceutical composition includes a medium and a plurality of cisplatin-loaded microbubbles dispersed in the medium. Each cisplatin-loaded microbubble includes a shell portion and a core portion. The shell portion includes a plurality of albumin molecules and a plurality of first cisplatin molecules covalently bonding to the albumin molecules. The core portion is surrounded by the shell portion, wherein the core portion includes a mixture of inert gas and a plurality of second cisplatin molecules. Ultrasound energy is then applied to a tumor of the subject to break the cisplatin-loaded microbubbles.

Abstract: Disclosed is a cosmetic composition for, e.g., use on eyelashes, that includes a latex polymer and a polyhydroxyalkanoate, where the polyhydroxyalkanoate is present in the composition in a total amount of between about 1% and about 5% by weight, and the monomers of the polyhydroxyalkanoate have carbon chain lengths of between 3 and 5.